In this paper, the global analysis of a HCV model with CTLs, antibody responses and therapy is studied. We incorporate into our model two treatments; the aim of the first one is to reduce the infected cells, while the second is to block the virus. We prove that the solutions with positive initial conditions are all positive and bounded. Moreover, we establish by using some appropriate Lyapunov functions that with the therapy the model becomes more stable than the one without treatment.
Introduction
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV). Approximately, 130 − 150 million people globally have chronic hepatitis C infection. Therefore, HCV infection presents a significant global public health issue [6] . For this reason, many mathematical models have been developed in order to understand the HCV dynamics [1, 5, 9] . In this article, we will consider the basic model presented by Wodarz in [9] and we will continue the investigation by introducing therapy into the model. It is well known that the antiviral therapies combined with interferon and ribavirin are successful in 90% of persons with acute infection and in 50% cases of persons with chronic infection [2] . The model of the HCV dynamics that we consider is under the following form:
the problem is supplemented by the initial conditions:
This model contains five variables, that is, uninfected cells (X), infected cells (Y), free virus (V), an antibody response (W) and a CTL response (Z).
Susceptible host cells (X) are produced at a rate λ, die at a rate dX and become infected by virus at a rate βXV . Infected cells die at a rate aY and are killed by the CTL response at a rate pY Z. Free virus is produced by infected cells at a rate kY and decays at a rate δV and is neutralized by antibodies at a rate qV W . CTLs expand in response to viral antigen derived from infected cells at a rate cY Z and decay in the absence of antigenic stimulation at a rate bZ. Antibodies develop in response to free virus at a rate gV W and decay at a rate hW . The parameter u 1 represents the efficiency of drug therapy in blocking new infection, so that infection rate in the presence of drug is β(1 − u 1 ), while the parameter u 2 stands for the efficiency of drug therapy in inhibiting viral production, such that the virion production rate under therapy is k(1 − u 2 ).
Clearly, the system (1) has a basic infection reproductive number of
The present paper is organized as follows. In section 2, we study the global existence of solutions, followed in section 3 by the analysis of the model. We discuss and conclude in the last section.
The global existence of solutions
In order to prove the global existence of solutions, we study the positivity and boundedness of solutions of system (1) describing the evolution of the cell population. For biological reasons, we assume that the initial data for this model satisfy :
Proposition 1. All solutions with non-negative initial conditions exist for all t > 0 and remain bounded and non-negative. Moreover we have
Proof For positivity, we show that any solution starting in non negative orthant From the first equation of the system (1), we deduce thatẊ + dX ≤ λ, then
Since 0 ≤ e −dt ≤ 1, we deduce (i). From the first and second equation of the system (1), we havė
Thus,
Using the integration by parts, we get
Therefore,
According to i), we have
hence,
From (3) and (4), we deduce (ii). Now, we prove iii). The third equation of system 1, and (V (t),
Since 1 − e −tδ ≤ 1, we deduce (iii). Using a same technique to show (2), we get
If h − δ ≥ 0, using (iii), we have
From (6) and (7), we deduce (iv). Finally, we prove v). The the fifth equation of system (1) implies thaṫ
Using the same techniques for the proof of (2) and (5), we get
From (8) and (9), we deduce (v).
Analysis of the model
In this section, we will prove that there exist a disease free equilibrium point and four endemic equilibrium points. Next, we will study the global stability of these equilibrium points.
By a simple calculation, the system (1) has always one disease-free equilibrium
, 0, 0, 0, 0) and four endemic equilibrium points:
where
In order to study the global stability of the points E 1 , E 2 , E 3 and E 4 , we define the following numbers:
aδh ,
Then, these equilibria can be written as follows:
It easy to remark that Remark 2.
1. If R 0 < 1, then the point E 1 does not exist and E 1 = E f when R 0 = 1. Proof. For the proof, we will use the same techniques given in [3, 7, 10] . We consider the following Lyapunov function defined in R 5 + by:
If H
is an equilibrium of the system. It easy to verifies thaṫ
).
For i = 0 we havė
thenV < 0 and E 0 is globally asymptotically stable, if R 0 ≤ 1. For i = 1 we have thaṫ
Using the arithmetic-geometric inequality, if R 0 > 1, we have
Using the arithmetico-geometric inequality, we have
Using the arithmetico-geometric inequality, we have 
The equality holds if and only if
X = X * and V Y = k(1−u 2 ) δ D Z 0 D W 0 = V * Y * . Let S = {(X, Y, V, W, Z) ∈ IR 5 + :V (X, Y, V, W, Z) = 0}. The trajectory (X(t), Y (t), V (t), W (t), Z(t)) ∈ S implies that Y = Y * , V = V * ,
Discussion and conclusion
In this work, we gave the global analysis of a HCV with CTL, antibody responses and therapy The disease free equilibrium is globally asymptotically stable if the basic infection reproduction number satisfies R 0 ≤ 1. For R 0 > 1, the global stability of the four endemic equilibrium points depends on both the basic defence rate by antibody response and the basic defence rate by CTL response. In addition, the goal of the therapy is to better control the concentrations of the virus and infected cells in order to reduce the value of the number of basic reproduction to a number below one. Indeed, if we put θ = u 1 + u 2 − u 1 u 2 which represents the combined efficacy of the two drugs, we will have 1 − θ = (1 − u 1 )(1 − u 2 ) which means that each drug acts independently. Hence, R 0 becomes
Then from the above formula of R 0 , we see that R 0 can be decreased by increasing the efficacy of therapy, i.e. increasing u 1 and u 2 (see Fig. 1 ).
